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Takehiko Mori,1 Jun Kato,1,2 Takayuki Shimizu,1 Yoshinobu Aisa,3 Tomonori Nakazato,3
Akiko Yamane,1,2 Yukako Ono,1 Hiroyoshi Kunimoto,1 Shinichiro Okamoto1Only limited data are available regarding the relationship between blood concentration of tacrolimus and its
efficacy in preventing acute graft-versus-host disease (aGVHD). We retrospectively evaluated the effects of
the whole blood concentration of tacrolimus, which was measured by an automated microparticle enzyme
immunoassay, early after allogeneic hematopoietic stem cell transplantation (HSCT) upon the development
of aGVHD. Sixty patients, who underwent allogeneic HSCT from serologically human-leukocyte antigen-
matched unrelated donors and received continuous infusion of tacrolimus with short-term methotrexate
for GVHDprophylaxis, were included in this study. The target range of the blood concentration of tacrolimus
was set at 10 to 20 ng/mL, and the level was maintained within this range in all patients. However, the mean
blood concentration of tacrolimus during the third week after HSCTwas significantly associated with the
grades of aGVHD (17.3 6 2.1 in patients with grades 0-I vs 15.9 6 2.8 in II-IV and 14.8 6 2.1 in III-IV; P
\ .05 and \.01, respectively). Multivariate analysis also demonstrated that higher age ($35) of
donor (odds ratio [OR] 5 4.28) and lower mean blood concentrations of tacrolimus during the second
(OR5 0.75; 95% confidence interval [CI]: 0.58-0.98) and third weeks (OR5 0.76; 95% CI: 0.58-0.98) after
HSCTwere significant risk factors for grades II-IV aGVHD (P\.05). We conclude that the early posttrans-
plantation blood concentration of tacrolimus had a significant impact on the development of moderate-
to-severe aGVHD after allogeneic HSCT from an unrelated donor.
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spite the introduction of calcineurin inhibitors such
as cyclosporine A (CsA) and tacrolimus. Tacrolimus
possesses 100 times greater in vitro inhibitory activity
against T cells than CsA, and has been widely used for
the prophylaxis of GVHD alone or in combination
with methotrexate (MTX) in patients undergoing allo-
geneic HSCT who are at high risk for developing
GVHD [1,2]. There have been 3 randomized trials
comparing the efficacy of CsA and tacrolimus in the
prophylaxis of GVHD after allogeneic HSCT, all of
which indicated that tacrolimus with short-term MTX
could prevent the development of acute GVHD
(aGVHD) more effectively than CsA with short-term
MTX [3-5]. However, the target ranges of the blood
concentration of tacrolimus early after transplantation
varied significantly among these 3 studies [3-5]. In
addition, the descriptions of the actual duration of
intravenous administration of tacrolimus, as well as229
Table 1. Patient and Donor Characteristics
No. of patients 60
Median age
years (range) 36 (12-56)
Sex
Male/female 41/19
Diagnosis
Acute leukemia 31
Chronic myelogenous leukemia 14
Myelodysplastic syndrome 7
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insufficient, and either of these parameters could
critically affect the drug’s efficacy. There have been
few studies that evaluated the optimal range of blood
concentration of tacrolimus early after allogeneic
HSCT for preventing aGVHD. Those studies clearly
demonstrated that a higher blood concentration of
tacrolimus was associated with its toxicity and
transplant-related mortality (TMR), but failed to dem-
onstrate any significant impact of blood concentration
of tacrolimus on the incidence of aGVHD [6,7]. Based
on these findings, a target range of 10 to 20 ng/mL of
tacrolimus was recommended. However, wide target
ranges of tacrolimus concentration were set in these
studies. In addition, the evaluations of tacrolimus
concentrations at a steady state of intravenous infusion
were compared rather haphazardly with those of the
trough levels of orally administered tacrolimus. We
previously showed that the 2 routes of administration
had significantly different pharmacokinetic profiles [8].
Therefore, we believe that it is necessary to reevaluate
the relationship between the tacrolimus blood
concentration and development of GVHD within the
steady-state target range between 10 and 20 ng/mL.
Recently, Watanabe et al. [9] reported a significant
relationship between the tacrolimus blood concentration
and incidence of aGVHDof grades II-IV in pediatric pa-
tients. They tried to maintain the blood concentration
within 5 to 15 ng/mL, and found that the incidence of
aGVHD of grades II-IV was 65.9% in patients with
a mean blood concentration #7 ng/mL and 34.8% in
those with a blood concentration .7 ng/mL. In this
study, we retrospectively evaluated the relationship be-
tween the blood concentration of tacrolimus within the
recommended range and the development of aGVHD
within its currently recommended blood concentration
in adult patients who underwent allogeneic HSCT
from serologically human leukocyte antigen (HLA)-
matched unrelated donors.Malignant lymphoma 6
Aplastic anemia 2
HLA compatibility
Serologically match 60
Class I (A and B)
Allele match 43
Allele mismatch 10
Data not available 7
Class II (DRB1)
Allele match 45
Allele mismatch 15
Median age of donor
Years (range) 34 (20-53)
Gender of donor
Male/female 37/23
Conditioning
Myeloablative 59
Reduced intensity 1
Methotrexate doses for GVHD prophylaxis
Four doses (days 1, 3, 6, and 11) 25
Three doses (days 1, 3, and 6) 35
HLA indicates human leukocyte antigen; GVHD, graft-versus-host
disease.PATIENTS AND METHODS
Patient and Donor Characteristics
Patients with hematologic disorders who underwent
allogeneicHSCT from an unrelated donor at Keio Uni-
versity Hospital were retrospectively evaluated. The in-
clusion criteria were as follows: (1) T cell-repleted
transplantation from an HLA-A, B, and DR serologi-
cally matched unrelated donor; (2) use of tacrolimus
and short-term MTX for GVHD prophylaxis; (3) ad-
ministration of tacrolimus intravenously for at least 3
weeks after transplantation without permanent discon-
tinuation; and (4) regular measurement of the whole
blood tacrolimus concentration at least 4 times in each
week. Among the 64 patients who underwent allogeneic
HSCT from an HLA-A, B, and DR serologicallymatched unrelated donor, 60 patients fulfilled the crite-
ria and were included in the analysis. Four patients were
excluded because of early discontinuation of tacrolimus
because of multiple organ failure (n5 2), disease relapse
(n 5 1), and early switch from intravenous to oral (n 5
1). The source of stem cells was bone marrow in all pa-
tients. The patient characteristics are shown in Table 1.
All patients underwent HSCT for the treatment of he-
matologic malignancies, with the exception of 2 patients
who had aplastic anemia. HLA-A and HLA-B antigens
were typed using standard serologic or low-
resolution techniques. HLA-A, B, and DRB1 alleles
were typed using high-resolution DNA techniques,
as described previously [10]. Fifty-nine patients
received myeloablative conditioning (total body
irridiation [TBI]-based, n5 58; busulfan1 cyclopho-
phamide, n 5 1), and 1 patient received a reduced-
intensity regimen (fludarabine 1melphalan).GVHD Prophylaxis
Tacrolimus was administered daily starting on day
–1 at a dose of 0.03 mg/kg by continuous intravenous
infusion, and the dose was adjusted to maintain the
whole-blood tacrolimus concentration between 10
and 20 ng/mL. The dose of tacrolimus had been
adjusted by each physician according to the whole-
blood tacrolimus concentration and adverse
events such as renal dysfunction. The whole-blood
Biol Blood Marrow Transplant 18:229-234, 2012 231Tacrolimus Concentration and GVHDconcentration of tacrolimus was measured by an auto-
mated microparticle enzyme immunoassay. The
administration of tacrolimus was switched from intra-
venous to oral when patients could reliably take oral
medication. Basically, MTX at a dose of 15 mg/m2
was given intravenously on day 1, followed by 10
mg/m2 on days 3, 6, and 11. MTX on day 11 was omit-
ted if the patients had severe infection, mucositis, and/
or liver dysfunction. Twenty-five patients received 4
doses, and 35 received 3 doses of MTX. Among the
35 patients who received 3 doses of MTX, 10 received
reduced doses of methotrexate (10 mg/m2 on day 1,
and 7 mg/m2 on days 3 and 6) according to the local
protocol. None of the patients received antithymocyte
globulin (ATG) for the prophylaxis of GVHD.
Diagnosis and Grades of aGVHD
The diagnosis of aGVHDwas made based on clin-
ical and pathological findings, and graded according to
the consensus criteria [11].
Statistical Analysis
The relation between the grades of aGVHD and
the concentrations of tacrolimus was evaluated using
the Jonckheere-Terpstra test. The difference between
the 2 groups was compared using the chi-square test,
the Fisher exact test, and Mann-Whitney U test as ap-
propriate. Multivariate analysis was performed using
multiple logistic regression analysis. P values \.05
were considered statistically significant.RESULTS
Relationship between the Incidence of Grades of
aGVHD and Concentration of Tacrolimus
Among the 60 patients, 13 patients (21.7%) devel-
oped grade I aGVHD, 20 (33.3%) developed grade II,
6 (10%) developed grade III, and 5 (8.3%) developed
grade IV (Table 2). Among the 31 patients with grades
II-IV aGVHD, 27 patients (87.1%) developed aGVHD
in the third week or later period after transplantation.
The mean blood concentrations of tacrolimus duringTable 2. Mean Tacrolimus Concentraion in Relation to
Grades of GVHD
Grades of GVHD N
Mean Concentration (±SD)
of Tacrolimus (ng/mL)*
0 16 17.2 ± 1.20†
I 13 16.9 ± 1.38†
II 20 16.1 ± 1.89†
III 6 16.3 ± 2.28†
IV 5 14.1 ± 2.30†
GVHD indicates graft-versus-host disease.
*Mean concentraion during the first 3 weeks after transplantation.
†Significant trend of decrease in relation to grades of GVHD by
Jonckheere-Terpstra test (P < .05).the first 3 weeks after transplantation ranged between
10.9 and 20.2 ng/mL (median: 16.6 ng/mL). In relation
to the grades of aGVHD, there was a significant trend
of lower mean concentration of tacrolimus during the
first 3 weeks after transplantation (P\ .05) (Table 2).
The comparative analysis of the concentration of
tacrolimus in each week during the first 3 weeks after
transplantation indicated that the mean concentration
of tacrolimus was significantly lower in patients with
grades II-IV aGVHD than those with grades 0-I
aGVHD in the second and third weeks after transplan-
tation (P \ .05) (Table 3). The same analysis also
indicated that the mean concentration of tacrolimus
was significantly lower in patients with grades III-IV
aGVHD than those with grades 0-I aGVHD in the
third week after transplantation (P \ .01) (Table 3),
but not in the second week. No significant differences
were observed in the analysis comparing the concen-
trations during the first week after transplantation
(Table 3).
Factors Affecting the Development of aGVHD
In addition to the concentration of tacrolimus, the
effects of patient age, patient sex, donor age, donor sex,
patient–donor sex match, HLA compatibility in class I
and II alleles, and the MTX doses on the incidence of
grades II-IV aGVHD were evaluated (Table 4). In
univariate analysis, older donor age, 3 doses of MTX
(vs 4 doses), and blood concentration of tacrolimus
were identified as significant factors for developing
grades II-IV aGVHD (Table 4). In multivariate analy-
sis, significant factors for developing grades II-IV
aGVHD included older donor age and mean tacroli-
mus blood concentration during the second and third
weeks each after transplantation (Table 4). Although
lower doses of MTX were not a significant factor by
univariate analysis, they showed a strong trend of asso-
ciation with aGVHD (P 5 .06) (Table 4).
Effects of Tacrolimus Concentration on Renal
Function
In all patients, the serum creatinine level was mea-
sured every day during the first month posttransplan-
tation. Among the 60 patients, the serum creatinineTable 3. Relationship between Grades of Acute GVHD and
Concentration of Tacrolimus at Each Week after Trans-
plantation
Grades
of GVHD N
Mean Concentration (±SD) of Tacrolimus (ng/mL)
First Week Second Week Third Week
0-I 29 17.3 ± 2.5 16.7 ± 1.9 17.3 ± 2.1
II-IV 31 16.7 ± 3.9* 15.0 ± 3.1† 15.9 ± 2.8†
III-IV 11 15.5 ± 4.8* 15.6 ± 2.7* 14.8 ± 2.1‡
GVHD indicates graft-versus-host disease; SD, standard deviation.
*Not significant compared with grades 0-I.
†Statistically significant compared with grades 0-I (P < .05).
‡Statistically significant compared with grades 0-I (P < .01).
Table 4. Univariate Analysis for Factors Affecting the Incidence of Acute GVHD (Grades II-IV)
Factors
Univariate Analysis
P Value
Multivariate Analysis
P ValueIncidence of Acute GVHD (%) Odds Ratio 95% CI
Patient sex Male versus female 53.7 versus 47.4 .78 — — —
Patient age (years) 35 or greater versus <35 56.3 versus 46.4 .61 — — —
Donor sex Male versus female 53.7 versus 47.4 .43 — — —
Donor age (years) 35 or greater versus <35 68.0 versus 40.0 .04 4.28 1.15-15.92 .03
Recipient/donor sex Match versus mimatch 48.0 versus 70.0 .30 — — —
HLA class I* Match versus mimatch 46.5 versus 70.0 .30 — — —
HLA class II Match versus mimatch 51.1 versus 53.3 1 — — —
MTX doses 4 doses versus 3 doses 37.1 versus 72.0 .01 3.44 0.97-12.26 .06
Tacrolimus conc. 2nd week Continuous variable † < .05† 0.75‡ 0.58-0.98 .03
Tacrolimus conc. 3rd week Continuous variable † < .05† 0.76‡ 0.58-0.98 .04
GVHD indicates graft-versus-host disease; CI, confidence interval; HLA, human leukocyte antigen; MTX, methotrexate; conc., concentration.
*Data were missing in 7 patients.
†The results are shown in Table 3.
‡For every increase of 1.0 ng/mL in blood concentration of tacrolimus.
232 Biol Blood Marrow Transplant 18:229-234, 2012T. Mori et al.level increased twofold or more during the first month
after transplantation as compared with that before
transplantation only in 3 patients (5%). There was
no significant correlation between the mean blood
concentration of tacrolimus during the 3 weeks of
the study period and the increase in serum creatinine
in all patients (r 5 0.11, P 5 .40). No patients devel-
oped posterior reversible encephalopathy syndrome.DISCUSSION
The prominent features of the present study com-
pared with other studies evaluating the relationship
between blood concentration of tacrolimus and
aGVHD were: (1) the blood concentrations of tacroli-
mus were all obtained during its continuous infusion;
(2) GVHD prophylaxis was tacrolimus and short-
term MTX in all cases; and (3) stem cell donors were
all serologically HLA-matched unrelated donors. Fur-
thermore, the target range of blood concentration had
been set at 10 to 20 ng/mL, which was strictly moni-
tored, and the mean concentration was successfully
maintained within the range in all the patients. In
this homogenous population, the blood concentration
of tacrolimus had a significant impact on the develop-
ment of grades II-IV aGVHD. Because a variety of fac-
tors reportedly affect the incidence of aGVHD, the
variation of those factors should be minimized to eval-
uate the efficacy of immunosuppressive therapy in pre-
venting aGVHD. Especially in regard to tacrolimus
administration, not only its actual blood concentration
but also the route of administration (continuous infu-
sion or oral) could have a significant effect on its effi-
cacy. In addition, the steady-state concentrations of
intravenous infusion and the trough levels of oral ad-
ministration were identically evaluated in the previous
study [6]. To avoid such potential confounders, this
study was designed to evaluate the relationship be-
tween the blood concentration of tacrolimus and the
development of aGVHDwithminimal effects on otherfactors. This may explain the discrepancy between this
study and other studies that did not demonstrate the
significance of this relationship [6,7]. On the other
hand, a recent report on pediatric patients by
Watanabe et al. [9] demonstrated a similarly signifi-
cant effect of blood concentration of tacrolimus on
the incidence of aGVHD; in their study, as in ours,
the blood concentrations of tacrolimus were evaluated
under continuous infusion (28 days, in their report) [9].
To our knowledge, their report and ours are the only 2
studies demonstrating a clear relationship between the
blood concentration of tacrolimus and the develop-
ment of aGVHD.
However, a number of important differences be-
tween the present study and the report of Watanabe
et al. [9] should also be discussed. The results of our
study indicated that a tacrolimus blood concentration
of 15 to 16 ng/mL constituted the dividing line be-
tween patients with grades 0-I aGVHD and those
with grades II-IV or III-IV aGVHD (Table 3), and
thus that 15 to 16 ng/mL might be the recommended
concentration for efficacious prophylaxis of aGVHD.
However, Watanabe et al. [9] have suggested that
this line should be 7 ng/mL. This difference could
be explained by the differences in target blood concen-
tration of tacrolimus between the 2 studies (10-20 vs
5-15 ng/mL). In addition, their study included recipi-
ents of allogeneic HSCT using various types of stem
cells and donors. Because the recipients of stem cells
from HLA-identical siblings or cord blood from
unrelated donors could be considered at lower risk of
developing aGVHD [5,12-15], this could also have
partly contributed to the difference in targeted blood
concentration of tacrolimus between the 2 studies. It
is possible that the recommended targeted blood
concentration of tacrolimus could be different among
the types of stem cell sources, and this should be
examined separately.
Tacrolimus shows its inhibitory activity against ac-
tivated T cells in vitro in a dose-dependent manner
Biol Blood Marrow Transplant 18:229-234, 2012 233Tacrolimus Concentration and GVHD[16-18]. The results of the present study clinically
support this observation. However, it should be
considered that tacrolimus also causes side effects,
such as nephrotoxicity, when its blood concentration
remains within the toxic range (presently considered
to be above 20 ng/mL) for a prolonged period [6,7].
Once its toxicity arises, physicians need to discontinue
the drug temporarily or decrease the target range.
Such an unexpected and unplanned dose adjustment
of tacrolimus is likely to increase the risk of
developing aGVHD, and this could be 1 of the
plausible explanations for the failure of the previous
reports to demonstrate the dose-dependent efficacy of
tacrolimus, because these reports applied wider and
higher (.20 ng/mL) target ranges [6,7]. Therefore,
our results suggest that the in vivo efficacy of
tacrolimus in preventing aGVHD is dose dependent
as long as its concentration is strictly maintained
within a less toxic therapeutic range.
In addition to the blood concentration of tacroli-
mus, we found that the donor age was also a significant
factor affecting the development of aGVHD.Older do-
nor age (35 years old or older) increased the incidence
of grades II-IV aGVHD with an odds ratio (OR) of
4.28 (95% confidence interval [CI]: 1.15-15.92). There
have been a series of reports evaluating the risk factors
for aGVHD, and diverse factors have been identified
[19-27]. However, the effect of donor age on aGVHD
remains controversial. Among those studies, only a
few studies identified donor age as a significant factor
affecting the incidence of aGVHD; in these studies,
older donor age significantly increased the incidence
of aGVHD [26,27].
Renal toxicity is 1 of the most common adverse ef-
fects of tacrolimus. In the present study, in which the
target level of tacrolimus was set at 10 to 20 ng/mL,
only 5% of the patients experienced renal impairment
defined by doubled serum creatinine levels compared
with those before transplantation. In addition, there
was no significant correlation between the concentra-
tion of tacrolimus and an increase in the serum creati-
nine level. In this study, the dose of tacrolimus was
adjusted on a daily basis, not only according to its
steady-state blood concentration of tacrolimus but
also the serum creatinine level. In addition, efforts,
such as hydration and dose adjustment of other neph-
rotoxic drugs concurrently given, weremade to correct
renal impairments. Therefore, our experience strongly
suggested that tacrolimus could be safely administered
at a concentration of 10 to 20 ng/mL if patients were
optimally managed.
In conclusion, physicians should recognize the
significance of early posttransplantation blood con-
centration of tacrolimus in preventing aGVHD, and
should maintain the concentration between 15 and
20 ng/mL. Further prospective studies are warranted
to evaluate the efficacy and safety of this target rangeof blood tacrolimus concentration in allogeneic
HSCT recipients.ACKNOWLEDGMENTS
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